Big Biopharma Trails Behind The Market: JP Morgan's 2025 Outlook on Eli Lilly, Merck, and MoreBenzinga • 12/22/24
Eli Lilly's Obesity Drug Wins Approval In Sleep Apnea; Will ResMed Dive?Investors Business Daily • 12/20/24
FDA approves Eli Lilly's weight loss drug Zepbound for sleep apnea, expanding use in U.S.CNBC • 12/20/24
FDA approves Zepbound® (tirzepatide) as the first and only prescription medicine for moderate-to-severe obstructive sleep apnea in adults with obesityPRNewsWire • 12/20/24
Eli Lilly: Improved Competitive Position In Obesity Market, But Strong Execution Is A Must NowSeeking Alpha • 12/20/24
LLY Stock Up as FDA Removes Mounjaro, Zepbound From Shortage ListZacks Investment Research • 12/20/24
Indiana Sees $39 Billion Worth of Projects Under Construction, an Industrial Info News AlertBusiness Wire • 12/20/24
Novo Nordisk Stock Crashes 22% After Disappoitning Obesity Drug Data. Eli Lilly Shares Soar.Barrons • 12/20/24
Focus: In weight loss battle, Novo and Lilly face growing offensive from licenced copiesReuters • 12/20/24